Echocardiography of the Right Heart in Pulmonary Arterial Hypertension: Insights from the ULTRA RIGHT VALUE Study

Aims: Outcome in pulmonary arterial hypertension (PAH) is determined by right ventricular (RV) function adaptation to increased afterload. Echocardiography is easily available to assist bedside evaluation of the RV. However, no agreement exists about the feasibility and most relevant measurements. We therefore examined the feasibility, quality, and clinical correlations of standard echocardiographic variables in the evaluation of PAH.

Methods And Results: The present multicentric study collected echocardiographic examinations with centralized reading in 401 patients with prevalent PAH. Clinical variables, as World Health Organization (WHO) functional class (FC), 6 min walk distance (6MWD), brain natriuretic peptide (BNP)/NT-proBNP, invasive haemodynamics, the European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines-derived four-strata score, and the United States Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) 2.0 score, were also collected. Echocardiographic measurements showed variable degrees of dilation of the right heart as assessed by right atrial and RV areas, altered indices of systolic function such as tricuspid annular plane systolic excursion (TAPSE), fractional area change, or 2D strain, and derived estimates of RV to pulmonary artery (PA) coupling by referring these measurements to systolic PA pressure (sPAP). All these measurements were feasible. All measurements of right heart dimensions and function, particularly TAPSE/sPAP, were correlated with WHO-FC, 6MWD, BNP/NT-proBNP, invasive haemodynamics, and ESC/ERS and REVEAL 2.0 scores.

Conclusion: The present quality-controlled data from a network of PAH referral centres offer the background needed for further evaluation of the added value of echocardiography to currently recommended risk assessments in PAH.

References

Hoeper M, Pausch C, Olsson K, Huscher D, Pittrow D, Grunig E . COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Eur Respir J. 2021; 60(1). PMC: 9260123. DOI: 10.1183/13993003.02311-2021. View

El-Kersh K, Zhao C, Elliott G, Farber H, Gomberg-Maitland M, Selej M . Derivation of a Risk Score (REVEAL-ECHO) Based on Echocardiographic Parameters of Patients With Pulmonary Arterial Hypertension. Chest. 2023; 163(5):1232-1244. PMC: 10268808. DOI: 10.1016/j.chest.2022.12.045. View

Badagliacca R, Raina A, Ghio S, DAlto M, Confalonieri M, Correale M . Influence of various therapeutic strategies on right ventricular morphology, function and hemodynamics in pulmonary arterial hypertension. J Heart Lung Transplant. 2017; 37(3):365-375. DOI: 10.1016/j.healun.2017.08.009. View

Gargani L, Pugliese N, De Biase N, Mazzola M, Agoston G, Arcopinto M . Exercise Stress Echocardiography of the Right Ventricle and Pulmonary Circulation. J Am Coll Cardiol. 2023; 82(21):1973-1985. DOI: 10.1016/j.jacc.2023.09.807. View

Badagliacca R, Ghio S, DAlto M, Ameri P, Correale M, Filomena D . Relevance of Echocardiography-derived Phenotyping in Patients with Pulmonary Arterial Hypertension Treated with Initial Oral Combination Therapy: An Italian Pulmonary Hypertension Network (iPHNET) Study. Am J Respir Crit Care Med. 2024; 210(3):362-365. DOI: 10.1164/rccm.202402-0431LE. View

Lang R, Badano L, Mor-Avi V, Afilalo J, Armstrong A, Ernande L . Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015; 16(3):233-70. DOI: 10.1093/ehjci/jev014. View

Tello K, Naeije R, de Man F, Guazzi M . Pathophysiology of the right ventricle in health and disease: an update. Cardiovasc Res. 2023; 119(10):1891-1904. DOI: 10.1093/cvr/cvad108. View

Vonk Noordegraaf A, Chin K, Haddad F, Hassoun P, Hemnes A, Hopkins S . Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. Eur Respir J. 2018; 53(1). PMC: 6351344. DOI: 10.1183/13993003.01900-2018. View

Badagliacca R, Reali M, Poscia R, Pezzuto B, Papa S, Mezzapesa M . Right Intraventricular Dyssynchrony in Idiopathic, Heritable, and Anorexigen-Induced Pulmonary Arterial Hypertension: Clinical Impact and Reversibility. JACC Cardiovasc Imaging. 2015; 8(6):642-52. DOI: 10.1016/j.jcmg.2015.02.009. View

10.

Rudski L, Lai W, Afilalo J, Hua L, Handschumacher M, Chandrasekaran K . Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology,.... J Am Soc Echocardiogr. 2010; 23(7):685-713. DOI: 10.1016/j.echo.2010.05.010. View

11.

Naeije R, Richter M, Rubin L . The physiological basis of pulmonary arterial hypertension. Eur Respir J. 2021; 59(6). PMC: 9203839. DOI: 10.1183/13993003.02334-2021. View

12.

Humbert M, Kovacs G, Hoeper M, Badagliacca R, Berger R, Brida M . 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022; 43(38):3618-3731. DOI: 10.1093/eurheartj/ehac237. View

13.

Brener M, Lurz P, Hausleiter J, Rodes-Cabau J, Fam N, Kodali S . Right Ventricular-Pulmonary Arterial Coupling and Afterload Reserve in Patients Undergoing Transcatheter Tricuspid Valve Repair. J Am Coll Cardiol. 2022; 79(5):448-461. DOI: 10.1016/j.jacc.2021.11.031. View

14.

Ferrara F, Rudski L, Vriz O, Gargani L, Afilalo J, DAndrea A . Physiologic correlates of tricuspid annular plane systolic excursion in 1168 healthy subjects. Int J Cardiol. 2016; 223:736-743. DOI: 10.1016/j.ijcard.2016.08.275. View

15.

Tello K, Axmann J, Ghofrani H, Naeije R, Narcin N, Rieth A . Relevance of the TAPSE/PASP ratio in pulmonary arterial hypertension. Int J Cardiol. 2018; 266:229-235. DOI: 10.1016/j.ijcard.2018.01.053. View

16.

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

17.

Naeije R . Assessment of right ventricular function in pulmonary hypertension. Curr Hypertens Rep. 2015; 17(5):35. DOI: 10.1007/s11906-015-0546-0. View

18.

Badagliacca R, Papa S, Manzi G, Miotti C, Luongo F, Sciomer S . Usefulness of Adding Echocardiography of the Right Heart to Risk-Assessment Scores in Prostanoid-Treated Pulmonary Arterial Hypertension. JACC Cardiovasc Imaging. 2020; 13(9):2054-2056. DOI: 10.1016/j.jcmg.2020.04.005. View

19.

Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Heart J. 2015; 37(1):67-119. DOI: 10.1093/eurheartj/ehv317. View

20.

Rubin L, Naeije R . Sotatercept for pulmonary arterial hypertension: something old and something new. Eur Respir J. 2023; 61(1). DOI: 10.1183/13993003.01972-2022. View